The invention describes a miRNA which interferes with glucocorticoid signalling and can therefore be used as a therapeutic target for e.g. diabesity-related metabolic disorders.
Side effects limit the radio/chemotherapeutic doses used during cancer treatment. Rocaglamide A and derivatives show strong chemo- and radioprotective efficacy, are highly specific for normal cells and do not protect p53-deficient/mutated cancer cells.
Non-ribosomal peptides (NRPs) are secondary metabolites produced by microorganisms, e.g. bacteria and fungi. Unlike ribosomal protein bio-synthesis, non-ribosomal protein synthesis (NRPS) does not require mRNA. NRPs are a promising source of functional molecules such as antibiotics. The technology allows for the identification, high-throughput screening and easy purification of engineered NRPs by optical measures.
The technology allows for direct and indirect detection of cancer tissue. It deals with a pharmaceutical compound consisting of three subdomains: (A) for specific cell surface binding to neoplastic cells, (B) for binding radiometals via a chelator domain for e.g. PET, and (C) harboring a fluorescent dye moiety for optical detection. The combination of PET tracer and optical moiety enables the surgeon to localize the tumor preoperatively via PET/CT and intraoperatively through optical detection.
The present invention discloses an antibody which selectively binds SITR1 dependent on its activation status.
The invention discloses a measles virus based oncolytic tumor therapy. The virus encodes antibodies against CTLA-4 or PD-L1 and has proven effectiveness in a in vivo mouse tumor model.
The antibody recognizes the kinase HIPK2 only when phosphorylated at Thr880 and Ser882 and therefore can be used for predicting kinase activity.
The assembly and maintenance of functional nucleoli is essential for cell viability. DKFZ researchers developed anti-sense oligos that target Alu element-containing RNAs, which are essential for intact nucleoli, for cancer cell specific induction of apoptosis.
Combination therapy of wogonin or rocaglamide together with Bcl-2 inhibitors leads to increased efficacy of ABT-263, even in cancer cells which have acquired resistance to ABT-263, and without affecting proliferation of normal T cells and platelets.
Numerous studies have shown that selective inhibition of the MetAP-II subtype halts the growth of endothelial cells in culture, inhibits angiogenesis in animal models, and is a validated strategy for anti-angiogenic cancer therapy. In addition, MetAP-II has also emerged as a promising target for other indications, including malaria, rheumatoid arthritis, pulmonary hypertension, and obesity. So the invention describes the design of the small molecules which was guided by the chemical structure of fumagillin. The substances have drug-like substructures, exist in novel chemical space, and the active enantiomeric series has been identified. In addition data on solubility and in vitro plasma half life time are available.
The invention presents a new method for pseudonymizing e.g. patient identifiers in which the pseudonymmization service provider is unable to derive the patient identifier from the pseudonym, but rather this ability is assigned to an authorized third party (Ombudsman). This is achieved by asymmetric and symmetric encryption algorithms and key derivation functions in combination with a new algorithm to pseudonymize a patient identifier. The asymmetric and symmetric encryption algorithms used in the pseudonymization software are approved by the technical directive TR-03116 for eCard-Projects of the German Federal Government. The method/software can be used for pseudonymmization of any sensitive data if they are processed by third-party institutions e.g. patient samples for translational research or bank account data.
This humanized monoclonal antibody efficiently neutralizes HSV fully in-dependent of complement or immune effector cell recruitment and completely abrogates viral cell-to-cell spread, a key mechanism by which HSV escapes humoral immune surveillance.
The invention provides a cell based high-throughput screening system for agents that influence DNA methylation by determining the methylation status of an internal promoter.
The aim of radiation therapy is to eradicate a tumor without causing significant damage to contiguous normal tissue. For precise field shaping of the radiation beam multileaf collimators (MLC) have been broadly established. The linear servo MLC presented here provides various advantages over conventionally employed MLCs like reduced size and weight, dynamic leaf movements up to 4 m/s, direct fixation of the linear servo rod to the associated leaf and position sensors are implemented in the linear drives.
Modifications of histones are known to play a role in cancer altering accessibility of DNA for transcriptional processes. So detection methods for enzymes modifying histones are of urgent need. We established two hybridoma cell lines producing antibodies directed against HDAC11suitable for immunocytochemistry, chromatin IP, and Western Blot.
70-80% of newly diagnosed breast tumors account for hormone receptor positive breast cancer (also known as luminal breast cancer). The histologic grade of luminal breast cancer is often determined by semi-quantitative methods describing morphologic features related to the differentiation states of the tumor specimen. In order to make a clear-cut classification of luminal breast cancer as either “grade 1” (= low risk) or “grade 3” (= high risk) tumors, DKFZ researchers have developed a 3-protein marker set.
Rückmeldung
